EydisBio Receives $0.5M Grant to Support the Development of TAK1 Inhibitor Program for Alzheimer's Disease
Shots:
- The NIH’s National Institute on Aging has awarded $0.5M 1st phase SBIR grant to develop TAK1 inhibitors for AD, to be carried out with Dr. Jun Ninomiya-Tsuji's team at North Carolina State University, who are studying TAK1’s role in inflammatory diseases
- The company’s research identified TAK1 as a key regulator of TNF & glutamate signaling that leads to neuronal death & its inhibition prevented neuronal loss as seen in AD models. EydisBio has developed selective low nanomolar potency TAK1 inhibitors with oral bioavailability that reduced neuroinflammation & neuronal necrosis in preclinical studies
- The 1st phase SBIR grant will support further non-clinical research to verify these results & identify leads for future advancement
Ref: PR Newswire | Image: EydisBio
Related News:- Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
